Reducing oral steroid intolerability and drug costs for acute wheezers: A retrospective evaluation of a clinical management algorithm in a Pediatric Emergency Department. Issue 4 (13th January 2023)

• Record Type: Journal Article
• Authors: Davison, Gail; Ruddell, Josh; Trouton, Michelle; McDonald, Roisin; Kennedy, Ben; O'Neill, Vikki; McCann, Joseph; Bartholome, Brigitte; Steen, Heather; Shields, Mike D.; Mullen, Stephen
• Is Part Of: Pediatric pulmonology. Volume 58:Issue 4(2023)
• Page Start: 1012
• Page End: 1021
• Publication Date: 2023-01-13
• Subjects: asthma -- children -- steroids; Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.26286
• Languages: English
• ISSNs: 8755-6863

Abstract

Abstract: Project Aim: To retrospectively evaluate a clinical management algorithm for acute wheezers in a UK Pediatric Emergency Department (PED). Overview and Rationale: Acute wheezing attacks are a leading cause of PED attendances and inpatient admissions. Prednisolone, a routine treatment, is intolerable in almost one‐third of children, requiring repeated dosing, which may prolong length of stay (LOS). To address this problem, we: (1) developed an acute management algorithm (concise, single‐sided flow‐chart, instructing immediate management); (2) modified the OCS regime from prednisolone (1 mg/kg, 3‐day course) to dexamethasone (600 then 300 mcg/kg); (3) and disseminated guidance regionally. Written information—handouts, e‐mails, and posters—were followed‐up with verbal reinforcement. We implemented the algorithm in 2017 and revised it further in 2018. Evaluation: In 2019, we retrospectively collected data on 100 acute wheeze attendances (those requiring OCS, aged 2–14), between October and December in 2016, 2017, and 2018 ( n = 300), and assessed outcomes. Results: Over a 48‐month period, we reduced OCS intolerability by 67.2% and OCS drug costs by 85.8% (saving £41, 470.14), while not significantly influencing the other outcomes. Conclusions: Reduced intolerability and substantial cost savings can be achieved by implementing a structured acute pediatric wheeze algorithm and modifying the OCS to single‐dose dexamethasone (300 mcg/kg).